Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 1988-1989, 2007; 10.1373/clinchem.2007.092171
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rigalleau, V.
Right arrow Articles by Gin, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rigalleau, V.
Right arrow Articles by Gin, H.
Related Collections
Right arrow General Clinical Chemistry
(Clinical Chemistry. 2007;53:1988-1989.)
© 2007 American Association for Clinical Chemistry, Inc.

Letters to the Editor

The Combination of Cystatin C and Serum Creatinine Improves the Monitoring of Kidney Function in Patients with Diabetes and Chronic Kidney Disease

Vincent Rigalleau1,a, Marie-Christine Beauvieux2, Catherine Lasseur3, Philippe Chauveau3, Christelle Raffaitin1, Caroline Perlemoine1, Nicole Barthe4, Christian Combe3 and Henri Gin1

1 Nutrition-Diabétologie and
2 Biochimie, Hôpital Haut-Lévêque Pessac, France
3 Néphrologie and
4 Médecine Nucléaire Hôpital Pellegrin Bordeaux, France

aAddress correspondence to this author at: Nutrition-Diabétologie, Hôpital Haut-Lévêque, Avenue de Magellan, 33600 Pessac, France. Fax 33 5 57 65 60 79; e-mail vincent.rigalleau@wanadoo.fr.

The first 20% of the full text of this article appears below.


To the Editor:

Pucci et al. (1) recently reported their study of the use of cystatin C (cysC) to detect decreases in renal function in patients with diabetes. CysC had an advantage over other methods only for detecting very early impairment of renal function [glomerular filtration rate (GFR) < 90 and 75 mL · min–1 · (1.73 m2)–1], whereas detection of the 70 patients with GFR <60 studied by Pucci et al.(1) was not improved by use of cysC compared with conventional estimated GFR estimations (e-GFR) predicted by Cockcroft and Gault (CG) and Modification of Diet in Renal Disease (MDRD) equations. Better GFR estimations are required for those patients considered to have chronic kidney disease (CKD) according to the new American Diabetes Association recommendations, particularly to assess the progression of their CKD, which may not be accurately estimated by the CG and MDRD equations(2). Rule et al.(3) recently proposed a composite GFR . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.